AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14762410 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT display with compression
Number of subjects: 49
Study 14762410 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT display with compression
Number of subjects: 49
Study 14762410 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT display for grading of uncompressed images magnified to four times
Number of subjects: 49
Study 14762410 — intervention group
Group type: COMPARATOR
Intervention: CRT display
Number of subjects: 49
Study 11713130 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome X patients (n=40)
Number of subjects: 103
Study 11713130 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease patients (n=53)
Number of subjects: 103
Study 11713130 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=10)
Number of subjects: 103
Study 11713130 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CCS comparison
Number of subjects: 103
Study 9385910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 134
Study 9385910 — intervention group
Group type: COMPARATOR
Intervention: Isradipine
Number of subjects: 134
Study 3416079 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered (leukocyte-poor) blood products
Number of subjects: 112
Study 3416079 — intervention group
Group type: COMPARATOR
Intervention: Standard (control) blood products
Number of subjects: 112
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-sensitive adverse events
Number of subjects: 1998
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventability of adverse events
Number of subjects: 1998
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of nursing-sensitive adverse events
Number of subjects: 1998
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of nursing-sensitive adverse events
Number of subjects: 1998
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in adverse events
Number of subjects: 1998
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission type differences in adverse events
Number of subjects: 1998
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of adverse events
Number of subjects: 1998
Study 31810021 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on hospital stay
Number of subjects: 1998
Study 29229305 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU weekly for 12-14 weeks)
Number of subjects: 48
Study 29229305 — intervention group
Group type: COMPARATOR
Intervention: Routine protocol (control group)
Number of subjects: 48
Study 28853392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline prescribed in therapeutic doses for 12 months
Number of subjects: 7
Study 28853392 — intervention group
Group type: COMPARATOR
Intervention: High-intensity Cognitive Behavioural Therapy (CBT) delivered in 14 sessions
Number of subjects: 7
Study 26222482 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual multimodal screening
Number of subjects: 21733
Study 26222482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening (US)
Number of subjects: 21733
Study 26222482 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21733
Study 23571176 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvated vaccine
Number of subjects: 271
Study 21349542 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with HLHS born at term (≥37 weeks gestation)
Number of subjects: 406
Study 21349542 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with HLHS from low-poverty areas
Number of subjects: 406
Study 21349542 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HLHS cases
Number of subjects: 406
Study 21349542 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=4060)
Number of subjects: 406
Study 18339153 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/ml of both morphine and ketamine (Ketamine group, n=26)
Number of subjects: 56
Study 18339153 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/ml of morphine (Control group, n=30)
Number of subjects: 56
Study 18339153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine group
Number of subjects: 56
Study 18339153 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 23221287 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshplace intervention
Number of subjects: 233
Study 23221287 — intervention group
Group type: COMPARATOR
Intervention: Traditional food pantry control
Number of subjects: 233
Study 16362788 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (68-MeV protons)
Number of subjects: 10
Study 16362788 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiotherapy (SRT) with 6-MV photons
Number of subjects: 10
Study 12637791 — intervention group
Group type: EXPERIMENTAL
Intervention: sH group
Number of subjects: 95
Study 12637791 — intervention group
Group type: COMPARATOR
Intervention: H group
Number of subjects: 95
Study 12637791 — intervention group
Group type: COMPARATOR
Intervention: C group
Number of subjects: 95
Study 10434822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms kg‐1
Number of subjects: 20
Study 10434822 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 300 micrograms kg‐1
Number of subjects: 20
Study 7559293 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg bid
Number of subjects: 10
Study 7559293 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg bid
Number of subjects: 10
Study 7559293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2191769 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative serum carcinoembryonic antigen (CEA) levels
Number of subjects: 30
Study 2191769 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum CEA levels
Number of subjects: 30
Study 2191769 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA-positive rates
Number of subjects: 30
Study 2191769 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 30
Study 2191769 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial postoperative assay of serum CEA levels
Number of subjects: 30
Study 419163 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs (20 different types)
Number of subjects: 75
Study 419163 — intervention group
Group type: COMPARATOR
Intervention: Placebos (5 total)
Number of subjects: 75
Study 419163 — intervention group
Group type: COMPARATOR
Intervention: Placebos from various studies not used for the establishment of the classification rule (9 total)
Number of subjects: 75
Study 12166685 — intervention group
Group type: EXPERIMENTAL
Intervention: EchoScreen (Madsen Electronics/Fischer‐Zoth GmbH)
Number of subjects: 4248
Study 12166685 — intervention group
Group type: COMPARATOR
Intervention: ILO Otodynamics Ltd system
Number of subjects: 4248
Study 29396712 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 77
Study 29396712 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CogT)
Number of subjects: 77
Study 29396712 — intervention group
Group type: COMPARATOR
Intervention: Waiting time effects
Number of subjects: 77
Study 27209164 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab (150 mg daily of erlotinib and 15 mg/kg of bevacizumab intravenously on day 1 of every 21-day cycle)
Number of subjects: 200
Study 27209164 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 200
Study 27209164 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab
Number of subjects: 200
Study 24039147 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant pure soluble coffee (three increasing doses)
Number of subjects: 0
Study 22449552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 30
Study 22449552 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 30
Study 22449552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 30
Study 22449552 — intervention group
Group type: COMPARATOR
Intervention: Control (no anesthetic)
Number of subjects: 30
Study 20619460 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analog (PGA) in 1 eye
Number of subjects: 206
Study 18928908 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 0
Study 18928908 — intervention group
Group type: COMPARATOR
Intervention: Protein-rich balanced nutrient beverage (control)
Number of subjects: 0
Study 16352884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,450-ppm F toothpaste
Number of subjects: 1268
Study 16352884 — intervention group
Group type: COMPARATOR
Intervention: 440-ppm F toothpaste
Number of subjects: 1268
Study 12809961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 37.5 mg/APAP 325 mg combination tablets
Number of subjects: 318
Study 12809961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 11075306 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8866038 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith Laboratories nicardipine (30 mg) under fasted conditions
Number of subjects: 34
Study 8866038 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith Laboratories nicardipine under fed conditions
Number of subjects: 34
Study 1346793 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12
Study 1346793 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 12
Study 1346793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6396114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole 1% powder
Number of subjects: 200
Study 6396114 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole placebo
Number of subjects: 200
Study 31727154 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCs vaccination
Number of subjects: 21
Study 31727154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mDCs and pDCs vaccination
Number of subjects: 21
Study 31727154 — intervention group
Group type: EXPERIMENTAL
Intervention: All DC vaccines
Number of subjects: 21
Study 28914187 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally facilitated program (StrokeLink) using outreach workshops incorporating clinical performance feedback, patient outcomes (survival, quality of life at 90‐180 days), local barrier assessments to best practice care, action planning, and ongoing support.
Number of subjects: 843
Study 28914187 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 843
Study 26876425 — intervention group
Group type: EXPERIMENTAL
Intervention: Programme to Improve Well‐being (PIW) in addition to Cardiac Rehabilitation Programme (CRP)
Number of subjects: 108
Study 26876425 — intervention group
Group type: COMPARATOR
Intervention: Cardiac Rehabilitation Programme (CRP)
Number of subjects: 108
Study 25044072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based strategy (home visits and telephone reinforcement)
Number of subjects: 252
Study 25044072 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (medical follow-up)
Number of subjects: 252
Study 22413452 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 125 microg x kg(‐1) x min(‐1) for one minute followed by 40 microg x kg(‐1) x min(‐1)
Number of subjects: 20
Study 22413452 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving landiolol)
Number of subjects: 20
Study 20186140 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate mousse
Number of subjects: 50
Study 20186140 — intervention group
Group type: COMPARATOR
Intervention: Cottage cheese
Number of subjects: 50
Study 20186140 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate mousse and cottage cheese
Number of subjects: 50
Study 20186140 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate mousse vs. cottage cheese
Number of subjects: 50
Study 17664516 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care for depression
Number of subjects: 1801
Study 17664516 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study 16084433 — intervention group
Group type: EXPERIMENTAL
Intervention: New synchrony (S) and entropy (E) parameters derived from equilibrium radionuclide angiography
Number of subjects: 22
Study 16084433 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 22
Study 16084433 — intervention group
Group type: COMPARATOR
Intervention: SD of ventricular phase (SD Ø)
Number of subjects: 22
Study 12454559 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 171
Study 12454559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 10466236 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 0
Study 10466236 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 10466236 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation or mastectomy
Number of subjects: 0
Study 7588499 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy for 3 months
Number of subjects: 25
Study 7588499 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy
Number of subjects: 25
Study 7588499 — intervention group
Group type: COMPARATOR
Intervention: GHD patients (baseline)
Number of subjects: 25
Study 2317672 — intervention group
Group type: COMPARATOR
Intervention: Marlex mesh posterior rectopexy
Number of subjects: 29
Study 2317672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidectomy combined with sutured posterior rectopexy
Number of subjects: 29
Study 6990875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled powder of fenoterol
Number of subjects: 13
Study 6990875 — intervention group
Group type: COMPARATOR
Intervention: Aerosol administration of fenoterol
Number of subjects: 13
Study 30986513 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (scaling and root planing) during the first 6 months
Number of subjects: 74
Study 30986513 — intervention group
Group type: COMPARATOR
Intervention: Control group (later intervention group)
Number of subjects: 74
Study 28371936 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training
Number of subjects: 0
Study 28371936 — intervention group
Group type: COMPARATOR
Intervention: Global stretching, memory exercises, and health education sessions
Number of subjects: 0
Study 26728453 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video gaming (AVG)
Number of subjects: 13
Study 26728453 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (control)
Number of subjects: 13
Study 24508533 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-mph)
Number of subjects: 22
Study 24508533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22605570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice a day)
Number of subjects: 50
Study 22605570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20537140 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported medication side effects
Number of subjects: 1000
Study 20537140 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for medication side effects
Number of subjects: 1000
Study 20537140 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver problems and doctor's awareness of medications
Number of subjects: 1000
Study 17972435 — intervention group
Group type: EXPERIMENTAL
Intervention: IT‐program implementation in Big‐towns
Number of subjects: 1267
Study 17972435 — intervention group
Group type: EXPERIMENTAL
Intervention: IT‐program implementation in Small‐towns
Number of subjects: 1267
Study 17972435 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of IT‐programs in Big‐towns
Number of subjects: 1267
Study 17972435 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of IT‐programs in Small‐towns
Number of subjects: 1267
Study 17972435 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for IT‐program in Big‐towns
Number of subjects: 1267
Study 17972435 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for IT‐program in Small‐towns
Number of subjects: 1267
Study 17972435 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to IT‐program adoption
Number of subjects: 1267
Study 15860043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (weight-adjusted dose)
Number of subjects: 1000
Study 15860043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 12375548 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% vaginal flushings (140 ml every 6 hours until delivery)
Number of subjects: 244
Study 12375548 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 g intravenously (every 6 hours until delivery)
Number of subjects: 244
Study 9895397 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation and intrauterine insemination
Number of subjects: 932
Study 9895397 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination
Number of subjects: 932
Study 9895397 — intervention group
Group type: COMPARATOR
Intervention: Superovulation and intracervical insemination
Number of subjects: 932
Study 9895397 — intervention group
Group type: COMPARATOR
Intervention: Intracervical insemination
Number of subjects: 932
Study 7493434 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 3.15 MJ meal
Number of subjects: 0
Study 7493434 — intervention group
Group type: COMPARATOR
Intervention: Three 1.05 MJ meals given 30 min apart
Number of subjects: 0
Study 1724166 — intervention group
Group type: EXPERIMENTAL
Intervention: MK886 (oral leukotriene biosynthesis inhibitor)
Number of subjects: 0
Study 1724166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7071293 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention task (counting electrical stimuli to one of four fingers)
Number of subjects: 16
Study 31217318 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing online e‐cigarette advertisements
Number of subjects: 964
Study 29605629 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI rest‐dipyridamole scintigraphy in patients with DM (Dp)
Number of subjects: 24
Study 29605629 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐MIBI rest‐dipyridamole scintigraphy in patients without DM (NDp)
Number of subjects: 24
Study 26765419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (14 weeks, thrice per week)
Number of subjects: 38
Study 26765419 — intervention group
Group type: COMPARATOR
Intervention: Social program only (control group)
Number of subjects: 38
Study 24121009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Response Analyzer (ORA)
Number of subjects: 106
Study 24121009 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann tonometer
Number of subjects: 106
Study 24121009 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact tonometer
Number of subjects: 106
Study 22028719 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch Colposuspension (BC) with abdominal POP repair (group A)
Number of subjects: 47
Study 22028719 — intervention group
Group type: COMPARATOR
Intervention: POP repair alone without any anti‐incontinence procedure (group B)
Number of subjects: 47
Study 19491286 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1000
Study 19491286 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1000
Study 17766739 — intervention group
Group type: EXPERIMENTAL
Intervention: IV NTG (initial dose of 0.05 microg.kg(‐1).min(‐1), followed by 0.1 microg.kg(‐1).min(‐1))
Number of subjects: 30
Study 17766739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15240604 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Number of subjects: 0
Study 15240604 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from T(4) therapy
Number of subjects: 0
Study 15240604 — intervention group
Group type: COMPARATOR
Intervention: No transient therapy with T(3)
Number of subjects: 0
Study 12097994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream (Elidel)
Number of subjects: 0
Study 11489708 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI with pelvic phased-array coil
Number of subjects: 176
Study 9623263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive multifocal lens
Number of subjects: 50
Study 9623263 — intervention group
Group type: COMPARATOR
Intervention: Refractive multifocal lens
Number of subjects: 50
Study 7936174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at 0.1 mmol/kg body weight
Number of subjects: 78
Study 7936174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at 0.3 mmol/kg body weight
Number of subjects: 78
Study 7936174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection (both doses)
Number of subjects: 78
Study 3337574 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (Hibiclens) - showering both evening and morning
Number of subjects: 0
Study 3337574 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (Hibiclens) - showering evening only
Number of subjects: 0
Study 3337574 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (Betadine)
Number of subjects: 0
Study 3337574 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotion soap (Safe 'N Sure)
Number of subjects: 0
Study 3337574 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate (Hibiclens)
Number of subjects: 0
Study 1493935 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose AraC (2 x 10 mg/m2 subcutaneously days 1‐14) plus GM-CSF (2 x 150 micrograms protein/day subcutaneously)
Number of subjects: 82
Study 1493935 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 82
Study 835531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 450